Home/Immunovant/Frank Torti, MD, MBA

FT

Frank Torti, MD, MBA

Executive Chairman

Therapeutic Areas

Autoimmune Diseases Immunology

Immunovant Pipeline

Drug	Indication	Phase
Batoclimab	Thyroid Eye Disease (TED)	Phase 3
IMVT-1402	Healthy Volunteers / Broad Autoimmune	Phase 1

Leadership Team at Immunovant

Eric Venker, MD, PharmD

Chief Executive Officer

Christine Blodgett

Senior Vice President of Human Resources

Khira Gabliani, MBA

Chief of Staff to the CEO

Chief Financial Officer

Melanie Gloria, BSN

Chief Operating Officer

View full Immunovant profile